Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- ChecktodayChange DetectedDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check15 days agoChange DetectedDifference0.4%
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new version of the study protocol for a clinical trial evaluating the safety and efficacy of ibrutinib and pembrolizumab in patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Key details such as the study's non-randomized design, the allocation of patients to cohorts, and the involvement of collaborators have been clarified.SummaryDifference56%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.5%
- Check37 days agoChange DetectedDifference0.4%
Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.